In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for October-December 2007. Our data come from Windhover's Strategic Transactions Database.
Amanda Micklus and Maureen Riordan
We present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking-for October-December 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for October-December 2007. Our data come from Windhover's Strategic Transactions Database.
Amanda Micklus and Maureen Riordan
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.